Cutaneous melanoma

anti-PD-1 monoclonal antibody

Thesis

[KNOWN] Retain pembrolizumab as the established adjuvant control and comparator for post-resection melanoma studies. [INFERRED] The key next test is whether a biomarker-defined subgroup can achieve greater benefit than pembrolizumab alone after accounting for the positive intismeran benchmark.

Mechanism

[KNOWN] PD-1 blockade can restore antitumor T-cell activity in melanoma. [INFERRED] Its activity provides the immune-response backbone against which individualized neoantigen vaccination can be measured.

Kill experiment

Use archived randomized INTerpath-001 specimens to prespecify and test the proposed biomarker and treatment-by-biomarker interaction. If the subgroup is not reproducible and shows no clinically meaningful differential benefit or residual-risk signal, the proposed biomarker escalation premise is falsified.

individualized mRNA neoantigen vaccine plus anti-PD-1 antibody

Thesis

[KNOWN] INTerpath-001 reported improved recurrence-free survival and distant-metastasis-free survival versus pembrolizumab alone in completely resected stage IIB-IV melanoma. [INFERRED] The next increment is prospective identification of patients with residual molecular disease or weak vaccine immunogenicity who need an added intervention.

Mechanism

[KNOWN] Individualized mRNA-4157/V940 encodes patient-specific neoantigens, while pembrolizumab blocks PD-1 signaling. [INFERRED] Combining antigen delivery with checkpoint release may expand and sustain neoantigen-reactive T-cell responses.

Kill experiment

Analyze stored INTerpath-001 tumor, ctDNA, and immune-response samples with a prespecified MRD/immunogenicity classifier. If no reproducible high-risk or weak-response subgroup can be identified, or those variables do not predict relapse or added-treatment need, the proposed next-increment hypothesis is falsified.

anti-PD-1 plus anti-LAG-3 monoclonal antibodies

Thesis

[KNOWN] Nivolumab plus relatlimab is an established immunotherapy combination for unresectable or metastatic melanoma. [INFERRED] It could be tested after progression on pembrolizumab-based neoantigen therapy, particularly when relapse suggests an additional checkpoint-exhaustion component.

Mechanism

[KNOWN] Nivolumab blocks PD-1 and relatlimab blocks LAG-3. [INFERRED] Dual checkpoint inhibition may restore function in T cells that remain inadequately responsive to PD-1 blockade alone.

Kill experiment

Run a small randomized ex-vivo autologous relapse-tumor/TIL assay comparing nivolumab alone with the combination in LAG-3-positive, PD-1-exposed samples. If relatlimab produces no incremental target engagement, T-cell function, or tumor killing across the prespecified eligible panel, the proposed added-checkpoint mechanism is falsified.

BRAF inhibitor plus MEK inhibitor

Thesis

[KNOWN] Dabrafenib plus trametinib is a melanoma treatment for tumors carrying activating BRAF V600 alterations and has an adjuvant role in selected resected disease. [INFERRED] Molecularly selected combination therapy remains a rational post-resection comparator or salvage strategy alongside individualized immunotherapy.

Mechanism

[KNOWN] Dabrafenib inhibits mutant BRAF and trametinib inhibits MEK1/2 in the MAPK pathway. [INFERRED] Suppressing MAPK signaling may reduce growth of BRAF V600-driven residual melanoma and provide a non-overlapping strategy after immune relapse.

Kill experiment

Test a prespecified panel of patient-derived BRAF V600 melanoma organoids, including post-immunotherapy relapse samples, for phospho-ERK suppression and selective viability loss with the combination. If verified BRAF V600 models show neither target suppression nor selective growth inhibition, the proposed residual-disease/salvage rationale is falsified.

autologous tumor-infiltrating lymphocyte cell therapy

Thesis

[KNOWN] Lifileucel is an approved cellular therapy option for selected unresectable or metastatic melanoma after prior systemic treatment. [INFERRED] It could be evaluated for patients who relapse despite neoantigen vaccination and PD-1 blockade, where pre-existing tumor-reactive lymphocytes may offer a different source of antitumor immunity.

Mechanism

[KNOWN] Lifileucel consists of expanded autologous tumor-infiltrating lymphocytes. [INFERRED] Infusing a selected, expanded polyclonal T-cell population may bypass failure to generate sufficient vaccine-induced immunity.

Kill experiment

In a prespecified cohort of post-pembrolizumab/neoantigen relapse specimens, expand the available autologous TIL products and measure selective killing of autologous tumor versus matched normal cells. If products cannot be generated or show no reproducible tumor-selective killing, the proposed ability to bypass inadequate vaccine-generated immunity is falsified.

KIT tyrosine-kinase inhibitor

Thesis

[KNOWN] Imatinib has clinical activity in melanoma subsets with activating KIT alterations, although KIT-driven disease is uncommon in cutaneous melanoma. [INFERRED] A genotype-enriched study could test whether rare KIT-altered relapses are better treated with targeted therapy than with another empiric checkpoint combination.

Mechanism

[KNOWN] Imatinib inhibits KIT and other tyrosine kinases. [INFERRED] KIT inhibition could suppress signaling in melanoma cells dependent on activating KIT alterations.

Kill experiment

Test confirmed activating KIT-mutant cutaneous melanoma organoids against imatinib with phospho-KIT target-engagement and selective viability readouts. If imatinib fails to suppress KIT signaling or selectively inhibit growth in the prespecified KIT-dependent models, the proposed KIT-dependence rationale is falsified.

gp100-directed ImmTAC T-cell engager

Thesis

[KNOWN] Tebentafusp is an active therapy in HLA-A*02:01-positive uveal melanoma. [SPECULATIVE] It is a wrong-but-plausible decoy for cutaneous melanoma because it targets the melanoma-associated antigen gp100; its efficacy in cutaneous melanoma should not be assumed and would require a dedicated test.

Mechanism

[KNOWN] Tebentafusp redirects T cells toward gp100-positive, HLA-A*02:01-positive cells. [SPECULATIVE] Antigen density, HLA restriction, and the cutaneous melanoma microenvironment may be insufficient for meaningful activity outside its established disease context.

Why it died

The agent exists, but its established target disease is HLA-A*02:01-positive uveal melanoma, not cutaneous melanoma. The pack provides no clinical evidence for cutaneous melanoma and explicitly labels it a wrong-but-plausible decoy; shared gp100 expression is insufficient to establish disease targeting.

oral alkylating chemotherapy

Thesis

[KNOWN] Temozolomide has been studied in metastatic melanoma but is not an established preferred treatment for modern cutaneous melanoma. [SPECULATIVE] It is a wrong-but-plausible decoy because an oral cytotoxic could appear attractive for reducing microscopic residual disease, yet there is no basis in this pack to expect it to improve outcomes after individualized mRNA vaccination and PD-1 blockade.

Mechanism

[KNOWN] Temozolomide produces DNA damage through alkylation. [SPECULATIVE] DNA damage might increase tumor-cell death or antigen release, but whether that would improve neoantigen-immunotherapy efficacy in resected melanoma is unsupported.

Kill experiment

A randomized melanoma study in the proposed residual-disease or post-immunotherapy setting showing no improvement over the relevant control, or unacceptable toxicity without benefit, would falsify the proposed use.

Why it died

Temozolomide is a real drug, but the pack provides only a generic DNA-alkylation mechanism followed by speculative tumor-cell death or antigen release. It skips the required melanoma-specific causal step connecting DNA damage to improved control of microscopic residual disease after mRNA vaccination and PD-1 blockade. The candidate is explicitly [SPECULATIVE], is not an established preferred modern melanoma treatment, and has no supported rationale for this setting.